Cargando…

Dalbavancin in clinical practice in Spain: a 2 year retrospective study

OBJECTIVES: Dalbavancin is approved for the treatment of acute bacterial skin and skin-structure infections (ABSSSIs) in adults. Its unique pharmacokinetic properties allow daily dosing to be avoided. The objective was to describe the sociodemographic and clinical characteristics of patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morata, Laura, Aguado, José María, Salavert, Miguel, Pasquau, Juan, Míguez, Enrique, Muñoz, Patricia, Rosselló, Irantzu, Almirante, Benito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777743/ https://www.ncbi.nlm.nih.gov/pubmed/36570687 http://dx.doi.org/10.1093/jacamr/dlac120

Ejemplares similares

Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
por: Rubio-Terrés, Carlos, et al.
Publicado: (2019)

Biomarkers of fungal infection: Expert opinion on the current situation
por: Bouza, Emilio, et al.
Publicado: (2020)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR)
por: Bouza, Emilio, et al.
Publicado: (2020)

DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci
por: Hidalgo-Tenorio, Carmen, et al.
Publicado: (2019)

Tedizolid: new data and experiences for clinical practice
por: Lletí, Miguel Salavert, et al.
Publicado: (2021)

A Multicentre, Prospective, and Retrospective Registry to Characterize the Use, Effectiveness, and Safety of Dalbavancin in German Clinical Practice
por: Hanses, Frank, et al.
Publicado: (2022)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

314. A Retrospective Review of Dalbavancin Utilization at an Academic Medical Center
por: Napoli, Emma, et al.
Publicado: (2020)

Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report
por: Otero, Judith Álvarez, et al.
Publicado: (2019)

A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing
por: Díaz-Navarro, Marta, et al.
Publicado: (2022)

108. Efficacy of Dalbavancin Compared to Standard of Care for the Treatment of Osteomyelitis: A Retrospective Study
por: Cain, Alexander, et al.
Publicado: (2021)

Correction to: A Dalbavancin Lock Solution Can Reduce Enterococcal Biofilms After Freezing
por: Díaz-Navarro, Marta, et al.
Publicado: (2022)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2021)

Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2022)

Global trends of dalbavancin: A bibliometric analysis
por: Monteagudo‐Martínez, Nuria, et al.
Publicado: (2022)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

In Vitro Efficacy of Dalbavancin as a Long-Acting Anti-Biofilm Agent Loaded in Bone Cement
por: Sánchez-Somolinos, Mar, et al.
Publicado: (2023)

A Dalbavancin for Successful Treatment of Infective Endocarditis Caused by Enterococcus faecalis
por: Teigell-Muñoz, Francisco Javier, et al.
Publicado: (2023)

Dalbavancin versus standard of care for the treatment of osteomyelitis in adults: A retrospective matched cohort study
por: Almangour, Thamer A., et al.
Publicado: (2020)

1813. A Retrospective Review of the Safety and Efficacy of Dalbavancin at Ireland's Largest Acute Medical Hospital
por: Conlon, Peter, et al.
Publicado: (2023)

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
por: Carrothers, Timothy J., et al.
Publicado: (2019)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

122. Dalbavancin Use in Patients with Substance Use Disorders
por: Streifel, Amber C, et al.
Publicado: (2020)

Use of dalbavancin in infective endocarditis: a case series
por: Guleri, Achyut, et al.
Publicado: (2021)

614. Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2021)

1004. Dalbavancin Use and Associated Cost-Savings: An Update
por: Streifel, Amber C, et al.
Publicado: (2022)

Dalbavancin in Bone and Joint Infections: A Systematic Review
por: Lovatti, Sofia, et al.
Publicado: (2023)

599. Dalbavancin Utilization in Rural Healthcare Setting: A Single Center Three Years’ Experience
por: AlSalman, Ahmad, et al.
Publicado: (2020)

Dalbavancin as suppressive antibiotic therapy in patients with prosthetic infections: efficacy and safety
por: Ruiz-Sancho, Andrés, et al.
Publicado: (2023)

P03 A retrospective review of the safety and efficacy of dalbavancin at Ireland’s largest acute medical hospital
por: Conlon, Peter, et al.
Publicado: (2023)

The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
por: Dowell, J, et al.
Publicado: (2008)

Dalbavancin safety in the phase 2/3 clinical development program
por: Seltzer, E, et al.
Publicado: (2008)

Anti-cooperative ligand binding and dimerisation in the glycopeptide antibiotic dalbavancin
por: Cheng, Mu, et al.
Publicado: (2014)

In Vitro Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against Clostridium difficile
por: Binyamin, Dana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_c7ku3cukck51mva57vr3vsnhm4